男性乳腺癌分子分型和预后预测的研究现状  

Molecular subtyping and prognostic prediction in male breast cancer

作　　者：郭美琴[1] 侯志超[1] 宋伟[1] 毕玮琳 Guo Meiqin;Hou Zhichao;Song Wei;Bi Weilin(Department of Breast Surgery,Second Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第二医院乳腺外科,太原030001

出　　处：《中华乳腺病杂志（电子版）》2021年第3期131-136,共6页Chinese Journal of Breast Disease(Electronic Edition)

摘　　要：男性乳腺癌是罕见病,患者生存期比女性乳腺癌差,迄今为止尚未在分子基因水平得到充分研究,大多借鉴女性乳腺癌的各种基础和临床研究对男性乳腺癌的诊治和预后进行推断,因此了解男性乳腺癌的分子分型和预后预测对其治疗的选择十分重要。笔者重点针对男性乳腺癌的分子分型和预后因素进行综述,以期为男性乳腺癌的治疗和预后判断提供帮助。Breast cancer is rare in males.Male patients have worse survival compared with female patients.The molecular genetic mechanism of male breast cancer has not been fully explored so far.The diagnosis,treatment and prognosis of male breast cancer in most studies are based on basic and clinical studies of female breast cancer.The molecular subtyping and prognosis prediction of male breast cancer are important for its treatment.This paper reviewed the molecular subtypes and prognostic biomarkers of male breast cancer in order to provide references for treatment and prognosis prediction of male breast cancer.

关 键 词：乳腺肿瘤 男性 分子分类 预后 

分 类 号：R737.9[医药卫生—肿瘤]